Bioventus Inc. logo

Bioventus Inc. (BVS)

Market Closed
11 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
8. 68
-0.37
-4.0884%
Pre Market
$
8. 80
+0.12 +1.3825%
589.41M Market Cap
- P/E Ratio
- Div Yield
582,797 Volume
- Eps
$ 9.05
Previous Close
Add Transaction
Day Range
8.66 9.13
Year Range
5.81 11.25
Want to track BVS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

BVS closed today lower at $8.68, a decrease of -4.0884% from yesterday's close, completing a monthly decrease of -11.8782% or -$1.17. Over the past 12 months, BVS stock gained 16.0428%.
BVS is not paying dividends to its shareholders.
The last earnings report, released on May 12, 2026, missed the consensus estimates by -0.1048%. On average, the company has fell short of earnings expectations by -0.023%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

BVS Chart

People also search for

Progyny Inc.
$ 25.65
-0.927%
Omnicell Inc.
$ 37.82
-0.9429%
AbCellera Biologics Inc.
$ 5.27
+3.5363%
Mesoblast Limited Sponsored ADR
$ 14.12
+2.3188%
Nanobiotix S.A. American Depositary Shares
$ 35.33
+5.3055%
Are Investors Undervaluing Bioventus (BVS) Right Now?

Are Investors Undervaluing Bioventus (BVS) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 2 days ago
Bioventus Highlights PNS, PRP Growth as Cash Flow Improves and Debt Falls

Bioventus Highlights PNS, PRP Growth as Cash Flow Improves and Debt Falls

Bioventus NASDAQ: BVS executives outlined the company's portfolio strategy, growth priorities and capital allocation plans during a Goldman Sachs event hosted by Jenny Rabinowitz, an analyst covering U.S. medtech and healthcare IT.

Marketbeat | 3 days ago
Bioventus Inc. (BVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Bioventus Inc. (BVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Bioventus Inc. (BVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seekingalpha | 3 days ago

Bioventus Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
Juniper Investment Company
Juniper Investment Company Juniper Investment Company LLC
6.94M $54,270.67 $60.16M $60.11M 110,759.56%
JC
Joseph Castro Nuveen LLC
148,662 $1.36M $1.29M -$69,842.92 -5.13%
JG
Jennifer Grunberg Allspring Global Investments Holdings LLC
79,913 $711,496.63 $693,644.84 -$17,851.79 -2.51%
BA
Bobby Adusumilli SJS Investment Consulting Inc.
16 $119.04 $138.88 $19.84 16.67%
AI
Ana-Maria Ignat Covestor Ltd
6,445 $52,838.62 $55,878.15 $3,039.53 5.75%

Bioventus Inc. (BVS) FAQ

What is the stock price today?

The current price is $8.68.

On which exchange is it traded?

Bioventus Inc. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is BVS.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 589.41M.

Has Bioventus Inc. ever had a stock split?

No, there has never been a stock split.

Bioventus Inc. Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Robert E. Claypoole CEO
NASDAQ (NGS) Exchange
09075A108 CUSIP
US Country
930 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Bioventus Inc. is a pioneering medical device company that places a strong emphasis on innovating and providing treatments aimed at enhancing the body's intrinsic healing mechanisms. Operating both in the United States and internationally, the company has carved a niche for itself in the medical device industry by offering a wide range of products designed for pain management, surgical solutions, and restorative therapies. With its foundation in 2011 and headquarters in Durham, North Carolina, Bioventus stands as a beacon of advancement in leveraging medical technology to improve patient outcomes.

Products and Services

Pain Treatments: Bioventus' portfolio addresses non-surgical pain through injection therapies and peripheral nerve stimulation products. Key offerings include:

  • Durolane: A treatment for knee osteoarthritis providing pain relief.
  • GELSYN-3: A series of injections for knee osteoarthritis pain management.
  • SUPARTZ: An injectable solution for knee osteoarthritis.
  • Stimrouter: A device aimed at treating chronic peripheral pain.

Surgical Solutions: The company provides surgeons with innovative tools and biomaterials for bone and soft tissue procedures, featuring:

  • Bone Graft Substitutes: Products like Osteoamp, Exponent matrix, Purebone, Signafuse bone graft, Interfuse bone graft, Osteomatrix+ synthetic bone graft, designed to stimulate bone healing.
  • Ultrasonic Products: High-precision devices such as nexus ultrasonic surgical system, bonescalpel surgical solution, SonaStar, and SonicOne ultrasonic cleansing and debridement system for surgeries, including minimally invasive procedures.
  • Extractor: A tool for autologous cell and bone marrow extraction to aid in bone healing.
  • Reficio Bone Matrix: A novel bone graft substitute.

Restorative Therapies: Bioventus also addresses neurologic and musculoskeletal recovery, offering devices that aid in rehabilitation from strokes, multiple sclerosis, or central nervous system disorders. Products include:

  • Exogen: A bone healing system.
  • L300 GO: A system designed to improve foot drop conditions caused by central nervous system disorders.
  • H200 Rehabilitation System: A solution to aid in regaining hand function.
  • Vector: A body weight support system for gait and balance training.
  • Bioness Integrated Therapy System: Offers comprehensive solutions for neurorehabilitation.

The company is also developing the Talisman Pulse Generator and Receiver, a potential breakthrough for peripheral nerve stimulation, showcasing Bioventus' commitment to ongoing innovation and improvement in the field of medical devices.

Contact Information

Address: 4721 Emperor Boulevard
Phone: 919 474 6700